COVID-19 is linked with hypercoagulability and higher thrombotic risk in terminally ill patients. In this observational cohort study of 412 COVID-19 patients, the use of aspirin or acetylsalicylic acid was linked with a significantly decreased mechanical ventilation, intensive care unit (ICU) admission, and mortality risk following the adjustment for confounding variables.

To examine if the use of aspirin is linked with lessened risk of mechanical ventilation, ICU admission, and mortality in the hospital.

Four hundred twelve adult patients admitted with COVID-19 to multiple hospitals were considered for this study. The requirement for mechanical ventilation was the primary outcome. ICU admission and mortality in the hospital were the secondary outcomes. 

Apart from 314 patients (76.3%), 98 patients (23.7%) got aspirin within 1 day of the hospital admission or 7 days prior to the admission. Aspirin use had a crude association with reduced mechanical ventilation and ICU admission, but no crude association with mortality as shown in the below table:

Aspirin use was independently linked with lower risk of mechanical ventilation, ICU admission, and in-hospital mortality after adjustment for 8 confounding variables. No variations in major bleeding or overt thrombosis amongst users and non- users of aspirin were found.

Aspirin or acetylsalicylic acid may be linked with better outcomes in patients who are hospitalized due to Coronavirus. Future studies are required to evaluate whether a connecting relationship is present between aspirin use and decreased lung injury and mortality in patients suffering from COVID-19.